Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
Phase 2
Completed
- Conditions
- Primary Peritoneal CarcinomaOvarian CancerUterine CancerCervical CancerFallopian Tube CancerBreast CancerEndometrial Cancer
- Interventions
- Biological: Vigil
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Mary Crowley Medical Research Center
- Target Recruit Count
- 13
- Registration Number
- NCT02725489
- Locations
- 🇺🇸
Mary Crowley Cancer Research Center, Dallas, Texas, United States
Blood for Immune Response to Provenge® in HRPC
Withdrawn
- Conditions
- Prostate Cancer
- First Posted Date
- 2011-01-11
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- Mary Crowley Medical Research Center
- Registration Number
- NCT01274572
Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer
Phase 1
Terminated
- Conditions
- Carcinoma, Advanced Metastatic
- Interventions
- Biological: TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Mary Crowley Medical Research Center
- Target Recruit Count
- 46
- Registration Number
- NCT00684294
- Locations
- 🇺🇸
Mary Crowley Cancer Research Centers, Dallas, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath